Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TSN084 |
| Synonyms | |
| Therapy Description |
TSN084 is a multi-kinase inhibitor with activity against Met, Flt3, Trk, Ddr1, and Cdk8/19, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 4027). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TSN084 | TSN-084|TSN 084 | CDK8 Inhibitor 5 DDR1 Inhibitor 10 FLT3 Inhibitor 69 MET Inhibitor 59 Trk Receptor Inhibitor (Pan) 33 | TSN084 is a multi-kinase inhibitor with activity against Met, Flt3, Trk, Ddr1, and Cdk8/19, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 4027). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05300438 | Phase I | TSN084 | Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. | Active, not recruiting | USA | 0 |